This educational activity will improve the clinical competence of clinicians to design, initiate, and advance antidiabetes medication treatments to achieve guideline-recommended goals at that key juncture where many of the more traditional treatments are insufficient or undesirable. Key areas of focus include clinician knowledge of the parameters of glycemic control, and in that context, the characteristics of three key therapeutic classes: the DPP-4 inhibitors, the GLP-1 receptor agonists, and the SGLT2 inhibitors. Emphasis will be placed on individualizing treatment design based on the mechanism of action of each class, its benefits, indications and contraindications, utilization in an individualized therapeutic treatment design, and medication titration to achieve goals. Also, in order to support patient achievement of individualized glycemic goals, this education aims to increase awareness of obstacles emanating from patients, as well as from providers and their care delivery systems, in order to identify steps to improve upon them.
The Evolution of Basal Insulins: One Small Step or a Giant Leap? is planned as part of a real-time virtual grand rounds series that captures the spirit of a traditional in-person live grand rounds meeting. The content of these programs will all relate to the care of some aspect of diabetes and/or one of its related conditions or comorbidities. The session will consist of faculty presentations of didactic material which will be enhanced by discussions about clinical interpretations and applications.
SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes: Methodology and Monitoring Impact is planned as part of a real-time virtual grand rounds series that captures the spirit of a traditional in-person live grand rounds meeting. The content of these programs will all relate to the care of some aspect of diabetes and/or one of its related conditions or comorbidities. The session will consist of faculty presentations of didactic material which will be enhanced by discussions about clinical interpretations and applications.
The New Insulins are Coming: What Does This Mean to the Practicing Clinician? is a virtual symposium series consisting of four (4) 60-minute sessions presented exclusively online at www.DiabetesSeriesLive.com. The live, virtual symposium series will include all of the features of a “live” clinical meeting, but will take place entirely online. The sessions will feature video-based streaming lectures, debates, panel discussions, case presentations, interactive activities such as polling and question and answer with expert presenters, and facilitated interaction with peers and other participants. Participants will be able to attend the live, virtual symposium series at their convenience, removing the limitation of time and expense of travel associated with a physical meeting. The live, virtual sessions will be recorded and hosted as an enduring educational activity certified for continuing medical education (CME) credit on DiabetesSeriesLive.com for six months after the live, virtual CME activity.
The introduction of new medications makes this a very exciting time to be managing patients with diabetes. Learn more about some of your newer options with Dr. Stephen Brunton as he discusses “Combining a Glucagon-like Peptide-1 Receptor Agonist with Basal Insulin: The Why and How,” a 1.0 hr CME accredited webinar.
Despite the implementation of government quality-improvement programs involving payment incentives and penalties to motivate clinicians to provide guideline-driven care, substantial quality gaps in glycemic control remain. More than half of type 2 diabetes mellitus (T2DM) patients do not reach HbA1c target goals, and many patients do not maintain glycemic control. The T2DM care team is large and includes not only the patient’s primary care provider, but also endocrinologists, diabetes educators, cardiologists, ophthalmologists, nurses, and several other care professionals. However, the patient must also be considered a member of the team, as patient behavior is the most important contributor to positive outcomes. Current T2DM care too often fails to leverage the positive impact of the active involvement of the patient. The multidisciplinary experts serving as faculty for this enduring activity will attempt to enhance coordination between patients and their caregivers and provide strategies for patient engagement to improve outcomes for T2DM patients.
Hypoglycemia is common in type 1 diabetes and also common in type 2 diabetes. Hypoglycemia unawareness can occur after repeated episodes of hypoglycemia and is of great concern due to the risk of severe hypoglycemia.
This activity will examine practical evidence-based techniques for selecting and implementing weight loss options to improve health outcomes in overweight patients. Focus will be on engaging patients to promote adherence in weight loss programs that meet their individual needs, including those that use weight loss medications.
This CME article will present the clinical realities of obesity encouraging an open provider/patient relationship that enhances care, allowing for discussions on goals, adherence, barriers, and expectations.
This activity will provide the participant with the latest up-to-date information for thyroid disease and review of treatment for both subclinical and overt disease. Discussion will include management of therapeutic options as well as counseling, screening, and monitoring the pregnant thyroid patient.
This educational activity will discuss appropriate screening and assessment for glycemia and associated comorbidities and review safety, efficacy, mechanisms of action, and place for non-insulin therapies within the treatment algorithm.
This activity was developed from the live Best Practices in Primary Care™ program held in Chicago, Illinois on June 21, 2014. The expert faculty will discuss the strategies pertaining to appropriate initiation and intensification of insulin therapy.
Hypogonadism is an underdiagnosed syndrome with links to age, obesity, type 2 diabetes mellitus (T2DM), and metabolic syndromes. This activity will help clinicians with appropriate screening, diagnosis, and available testosterone supplemental therapies.
With new advances in the understanding and treatment of T2DM, there is an increased need for healthcare professionals to understand the existing clinical data on this topic, and this CME program will address the rational use of SGLT2 inhibitors in patients with T2DM.
This Education Station™ activity will deal with diabetes, hypogonadism, and major depressive disorder. Primary care clinicians frequently encounter these chronic conditions and are expected to manage them routinely in daily practice. Tools, techniques, and strategies to overcome the barriers to effective management of these chronic conditions will be discussed in this Education Station™ activity.